As the cell and gene therapy (CGT) field progresses and the number of product approvals continues to grow, there is an increasing demand to incorporate higher-volume production to deliver potentially life-saving therapies to expanding patient populations. From May 16th-17th, 2024, the Alliance for Regenerative Medicine held a 1.5-day workshop on Advanced Manufacturing in CGT to cover various strategies for expanding manufacturing capabilities. The workshop brought together CGT therapeutic developers, technology developers, regulatory representatives, and other key stakeholders from across the industry to focus on three primary areas of opportunity: (1) automation & advanced processes/analytics, (2) artificial intelligence/machine learning (AI/ML), and (3) decentralized manufacturing models.
The full whitepaper is free for ARM members to access on our community portal. If you are not an ARM member, but would like to view the full document, you can purchase full access to the whitepaper here.
Full Whitepaper – Members Only Access
